305
Views
11
CrossRef citations to date
0
Altmetric
Letter to the Editor

Patients with relapsed follicular lymphoma treated with rituximab versus tositumomab and iodine I-131 tositumomab

, , , &
Pages 779-781 | Received 24 Feb 2014, Accepted 18 May 2014, Published online: 23 Jul 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Golshid Sanati, Zahra Aryan, Mehri Barbadi & Nima Rezaei. (2015) Innate lymphoid cells are pivotal actors in allergic, inflammatory and autoimmune diseases. Expert Review of Clinical Immunology 11:8, pages 885-895.
Read now

Articles from other publishers (10)

Sharafudeen Dahiru Abubakar, Stella Amarachi Ihim, Mansur Aliyu, Mohammad Saffarioun & Gholamreza Azizi. 2024. Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal. Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal 31 75 .
Aurélie Rondon, Jacques Rouanet & Françoise Degoul. (2021) Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials. Cancers 13:21, pages 5570.
Crossref
Chengxin Luo, Guixian Wu, Xiangtao Huang, Yanni Ma, Yali Zhang, Qiuyue Song, Mingling Xie, Yanni Sun, Yarui Huang, Zhen Huang, Yu Hou, Shuangnian Xu, Jieping Chen & Xi Li. (2021) Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis. Scientific Reports 11:1.
Crossref
O, A. Bezborodova, A. A. Pankratov, E. R. Nemtsova, Yu. B. Venediktova, M. S. Vorontsova, G. N. Engalycheva & R. D. Syubaev. (2020) Anti-Tumour Drugs: Planning Preclinical Efficacy and Safety Studies. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products 10:2, pages 96-110.
Crossref
Lee, Kim & Kim. (2019) Improved Quantification of 18F-FDG PET during 131I-Rituximab Therapy on Mouse Lymphoma Models after 131I Prompt Emission Correction. Diagnostics 9:4, pages 144.
Crossref
Luca Falzone, Salvatore Salomone & Massimo Libra. (2018) Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. Frontiers in Pharmacology 9.
Crossref
Sumimasa Nagai & Keiya Ozawa. (2018) Drug approval based on randomized phase 3 trials for relapsed malignancy: analysis of oncologic drugs granted accelerated approval, publications and clinical trial databases. Investigational New Drugs 36:3, pages 487-495.
Crossref
Isabel Corraliza-Gorjón, Beatriz Somovilla-Crespo, Silvia Santamaria, Jose A. Garcia-Sanz & Leonor Kremer. (2017) New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness. Frontiers in Immunology 8.
Crossref
Savita V. Dandapani & Jeffrey Wong. 2016. Antibody‐Drug Conjugates. Antibody‐Drug Conjugates 409 429 .
Jin Su Kim. (2016) Combination Radioimmunotherapy Approaches and Quantification of Immuno-PET. Nuclear Medicine and Molecular Imaging 50:2, pages 104-111.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.